<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="93896">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01882543</url>
  </required_header>
  <id_info>
    <org_study_id>AQX-1125-201</org_study_id>
    <nct_id>NCT01882543</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of AQX-1125 in IC/BPS</brief_title>
  <acronym>LEADERSHIP</acronym>
  <official_title>A Phase 2 Study to Evaluate the Efficacy and Safety of AQX-1125 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Mediated by the Src Homology-2-domain-containing Inositol 5' Phosphatase [SHIP1] Pathway</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aquinox Pharmaceuticals (Canada) Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aquinox Pharmaceuticals (Canada) Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the effect of 6 weeks of treatment with
      once daily administration of AQX-1125 compared to placebo on average daily pain in subjects
      with interstitial cystitis/bladder pain syndrome (IC/BPS), during and after treatment, using
      a standardized 11-point numerical rating scale (NRS) pain score recorded by electronic diary
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the mean daily bladder pain score</measure>
    <time_frame>6 weeks (also at 2 and 4 weeks)</time_frame>
    <description>Difference in the change from baseline in the mean daily bladder pain score based on an 11-point numeric rating scale [NRS] at 2, 4 and 6 weeks recorded by e-diary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in the change from baseline in other symptom scores and quality of life measures</measure>
    <time_frame>2, 4 and 6 weeks</time_frame>
    <description>Bladder Pain/Interstitial Cystitis Symptom Score [BPIC-SS], interstitial cystitis symptom index/problem index [ICSI/PI] and short form 12 version 2.0 health survey [SF-12v2] questionnaires will be completed at start and end of treatment (and BPIC-SS at 2 and 4 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety determined by adverse events [AEs], physical examinations, laboratory tests, electrocardiogram [ECG] and ophthalmic examinations</measure>
    <time_frame>10 weeks</time_frame>
    <description>Adverse events will be collected from signing of informed consent until discharge from study. Other assessments will be completed at regular intervals</description>
  </secondary_outcome>
  <other_outcome>
    <measure>AQX-1125 concentrations in plasma and urine (trough values)</measure>
    <time_frame>10 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Interstitial Cystitis</condition>
  <condition>Bladder Pain Syndrome</condition>
  <arm_group>
    <arm_group_label>AQX-1125</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 x AQX-1125 Capsule daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 x placebo capsule daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AQX-1125</intervention_name>
    <description>Synthetic SHIP1 activator</description>
    <arm_group_label>AQX-1125</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Double blind placebo capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be females, ≥18 and ≤75 years of age who have consistently had symptoms of bladder
             pain in addition to urinary urgency and/or urinary frequency for more than 12 months

          -  Have had the diagnosis of interstitial cystitis for &gt; 6 months (but pain for at least
             12 months) but ≤15 years

          -  Have average daily pain score of at least 5 out of 10 on the 11-point NRS pain scale
             in the 7 days prior to baseline

          -  Have undergone a cystoscopy and have documented visible signs of bladder bleeding,
             lesions or glomerulation within the last 36 months prior to baseline.

          -  Subjects if of child bearing potential, must agree to avoid pregnancy and use
             medically acceptable method of contraception from screening visit and throughout the
             study.

          -  Must be capable of voiding independently

        Exclusion Criteria:

          -  Pelvic floor pain (&gt;5 out of 10 on the 11-point NRS pain scale following a pelvic
             pain assessment)

          -  Have a body mass index [BMI] of &lt;18 kg/m2 or &gt;39 kg/m2

          -  Have had a urinary tract infection including bacterial cystitis within the past 30
             days.

          -  Have greater than 1+ hematuria on dipstick test at screening from an unknown cause

          -  History of previous procedure(s) (augmentation cystoplasty, cystectomy, or
             cystolysis) that has affected bladder function
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen B Shrewsbury, MD</last_name>
    <role>Study Director</role>
    <affiliation>Aquinox Pharmaceuticals (Canada) Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AQX/CMX site</name>
      <address>
        <city>Homewood</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AQX/CMX site</name>
      <address>
        <city>Glendora</city>
        <state>California</state>
        <zip>91741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AQX/CMX site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AQX/CMX site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AQX/CMX site</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AQX/CMX site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AQX/CMX site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AQX/CMX site</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AQX/CMX site</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AQX/CMS Site</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AQX/CMX site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AQX/CMX site</name>
      <address>
        <city>Desoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AQX/CMX site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2V1P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AQX/CMX site</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AQX/CMX Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AQX/CMX site</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AQX/CMX site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AQX/CMX site</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AQX/CMX site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AQX/CMX site</name>
      <address>
        <city>Brantford</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AQX/CMX site</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AQX/CMX site</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AQX/CMX site</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AQX/CMX site</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AQX/CMX site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Lesley Carr</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AQX/CMX site</name>
      <address>
        <city>Granby</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AQX/CMX site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AQX/CMX site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ichelp.org</url>
    <description>The Interstitial Cystitis Association (ICA) is the only nonprofit association dedicated solely to improving the quality of healthcare and lives of people living with interstitial cystitis (IC).</description>
  </link>
  <link>
    <url>http://www.bladderpainstudy.com</url>
    <description>Clinical trial for women with IC/BPS</description>
  </link>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 20, 2015</lastchanged_date>
  <firstreceived_date>June 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Interstitial cystitis</keyword>
  <keyword>Bladder pain syndrome</keyword>
  <keyword>IC/BPS</keyword>
  <keyword>AQX-1125</keyword>
  <keyword>SHIP1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Somatoform Disorders</mesh_term>
    <mesh_term>Cystitis</mesh_term>
    <mesh_term>Cystitis, Interstitial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
